Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims&Hers Health announced it may no longer sell compounded versions of semaglutide, the active ingredient in Novo’s weight-loss ...
Eli Lilly (NYSE:LLY) announced Tuesday it expanded its weight loss drug offerings, launching new 7.5 mg and 10 mg single-dose ...